

Asst. Prof. FATİH YULAK

Personal Information

Email: fatihyulak@cumhuriyet.edu.tr

Web: <https://avesis.cumhuriyet.edu.tr/105397>

International Researcher IDs

ORCID: 0000-0003-3708-6752

Publons / Web Of Science ResearcherID: GQH-7878-2022

Yoksis Researcher ID: 323309

Research Areas

Medicine, Health Sciences, Fundamental Medical Sciences, Human Physiology, Neurophysiology

Academic Positions

Research Assistant, Sivas Cumhuriyet University, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2020 - Continues

Journal articles indexed in SCI, SSCI, and AHCI

I. HER-2 SMASH

Alandağ C., ÖZTÜRK A., YULAK F., ŞAHİN İNAN Z. D., Karaca M., LAÇİN B. B., ALTUN A.
Cancer Chemotherapy and Pharmacology, vol.95, no.1, 2025 (SCI-Expanded)

II. Enoxaparin Protects C6 Glioma Cells from Glutamate-Induced Cytotoxicity by Reducing Oxidative Stress and Apoptosis

YULAK F., JOHA Z., ÖZTÜRK A., ŞAHİN İNAN Z. D., TAŞKIRAN A. S.
Molecular Neurobiology, vol.62, no.4, pp.4631-4640, 2025 (SCI-Expanded)

III. Tannic acid protects neuroblastoma cells against hydrogen peroxide – triggered oxidative stress by suppressing oxidative stress and apoptosis

YULAK F., ERGÜL M.
Brain Research, vol.1844, 2024 (SCI-Expanded)

IV. A PLK1 inhibitor, RO3280, suppresses proliferation of SNU-16 gastric cancer cells via apoptosis

YULAK F., Keskin Z.
Bangladesh Journal of Pharmacology, vol.19, no.2, pp.43-51, 2024 (SCI-Expanded)

V. Lycopene induces antiproliferative effects through apoptosis, autophagy, and oxidative DNA damage in the HeLa cells

PARLAK M., JOHA Z., YULAK F., Mendil A. S., TAŞTEMUR Y.
Journal of Receptors and Signal Transduction, vol.44, no.3, pp.115-121, 2024 (SCI-Expanded)

VI. Mechanism of anticancer effect of ETP-45658, a PI3K/AKT/mTOR pathway inhibitor on HT-29 Cells

YULAK F., FILİZ A. K., JOHA Z., ERGÜL M.
Medical Oncology, vol.40, no.12, 2023 (SCI-Expanded)

VII. FGF-18 alleviates memory impairments and neuropathological changes in a rat model of Alzheimer's disease

Ciltas A., Karabulut S., Sahin B., Filiz A. K., Yulak F., Ozkaraca M., Karatas Ö., Cetin A.

- Neuropeptides, vol.101, 2023 (SCI-Expanded)
- VIII. **Mechanism of anticancer effect of gambogic acid on gastric signet ring cell carcinoma**
Joha Z., Öztürk A., Yulak F., Karataş Ö., Ataseven H.
Medical Oncology, vol.40, no.9, 2023 (SCI-Expanded)
- IX. **GSK461364A suppresses proliferation of gastric cancer cells and induces apoptosis**
Ataseven D., Taştemur Ş., YULAK F., KARABULUT S., ERGÜL M.
Toxicology in Vitro, vol.90, 2023 (SCI-Expanded)
- X. **Anticancer activity of sinapic acid by inducing apoptosis in HT-29 human colon cancer cell line**
Taştemur Ş., Hacisüleyman L., KARATAŞ Ö., YULAK F., ATASEVEN H.
Canadian Journal of Physiology and Pharmacology, vol.101, no.7, pp.361-368, 2023 (SCI-Expanded)
- XI. **Death receptor-dependent apoptosis and cell cycle delay induced by bioymifi in human cervical cancer cells**
ALTUN A., ŞAHİN İNAN Z. D., YULAK F.
PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.35, no.4, pp.1031-1036, 2022 (SCI-Expanded)
- XII. **Synthesis of diaryl urea derivatives and evaluation of their antiproliferative activities in colon adenocarcinoma**
GÖMEÇ M., YULAK F., GEZEGEN H., ÖZKARACA M., SAYIN K., ATASEVEN H.
JOURNAL OF MOLECULAR STRUCTURE, vol.1254, 2022 (SCI-Expanded)
- XIII. **Mechanism of anti-cancer effect of beta-glucan on SH-SY5Y cell line**
FİLİZ A. K., Joha Z., YULAK F.
BANGLADESH JOURNAL OF PHARMACOLOGY, vol.16, no.4, pp.122-128, 2021 (SCI-Expanded)

Articles Published in Other Journals

- I. **Evaluation of the Antitumor Activity of Omipalisib, a PI3K/AKT/MTOR Pathway Inhibitor, on Burkitt Lymphoma Cell Line**
KESKİN Z., YULAK F., TERZİ H., İNANIR M.
Cumhuriyet Science Journal, vol.44, no.4, pp.635-639, 2023 (Peer-Reviewed Journal)
- II. **Investigation of The Antiproliferative Effect of Colchicine on SNU-1 Gastric Cancer Cells**
yulak f.
Cumhuriyet Science Journal, vol.44, no.2, pp.263-267, 2023 (Peer-Reviewed Journal)
- III. **Levetiracetam Protects Against Glutamate-Induced Excitotoxicity in SH-SY5Y Cell Line**
ÇETİNDAĞ ÇILTAŞ A., Gündoğdu S., YULAK F.
International Journal of Nature and Life Sciences, vol.6, no.2, pp.142-150, 2022 (Peer-Reviewed Journal)
- IV. **Investigation of the potential antitumor activity of PLK1 inhibitor SBE13 in colon cancer cell line HT29**
GÖMEÇ M., YULAK F., ERGÜL M.
Cumhuriyet Tıp Dergisi (ELEKTRONİK), vol.44, no.2, pp.218-222, 2022 (Peer-Reviewed Journal)
- V. **The Anticancer Effect of Cannabinoid 2 Agonist L-759,633 on C6 and SH-SY5Y Cell Lines**
Joha Z., Yulak F., Öztürk A., Şahin B., Yıldırım Ş.
Turkish Journal of Science and Health , vol.2, no.3, pp.6-13, 2021 (Peer-Reviewed Journal)

Metrics

Publication: 20

Citation (WoS): 6

Citation (Scopus): 52

H-Index (WoS): 2

H-Index (Scopus): 6